Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Editorial

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 3735 Download: 79 Web of Science: 4 Crossref: 3

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 4206 Download: 87 Web of Science: 3 Crossref: 3

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 4059 Download: 78 Web of Science: 3 Crossref: 3

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 4699 Download: 155 Web of Science: 3 Crossref: 3

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 4958 Download: 100 Web of Science: 2 Crossref: 2

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 4250 Download: 98 Web of Science: 4 Crossref: 4

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 3816 Download: 120 Web of Science: 2 Crossref: 1

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 3767 Download: 74 Web of Science: 6 Crossref: 7

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 4092 Download: 140 Web of Science: 9 Crossref: 8

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 8730 Download: 480 Web of Science: 44 Crossref: 48

Correspondence

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

View: 3605 Download: 51

Letter to the Editor

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

View: 3593 Download: 58

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

View: 3661 Download: 67

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 3889 Download: 59 Web of Science: 1 Crossref: 1

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0326

View: 4064 Download: 68 Web of Science: 1 Crossref: 1

Review

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 7209 Download: 269 Web of Science: 36 Crossref: 36

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 11172 Download: 201 Web of Science: 12 Crossref: 12

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 5841 Download: 158 Web of Science: 9 Crossref: 7

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 3945 Download: 78 Web of Science: 1 Crossref: 1

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 4078 Download: 121 Web of Science: 9 Crossref: 8

Original Article

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 6672 Download: 191 Web of Science: 34 Crossref: 34

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 9824 Download: 451 Web of Science: 31 Crossref: 33

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2022;28(4):814-826. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0099

View: 6314 Download: 215 Web of Science: 26 Crossref: 28

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 3558 Download: 74

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 3949 Download: 89 Web of Science: 4 Crossref: 5

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 9423 Download: 537 Web of Science: 51 Crossref: 50

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 6338 Download: 266 Web of Science: 15 Crossref: 18

Snapshot

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 6650 Download: 178 Web of Science: 14 Crossref: 13

Original Article

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

View: 9783 Download: 224 Web of Science: 61 Crossref: 62

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):553-564. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0082

View: 4451 Download: 101 Web of Science: 14 Crossref: 15

1 | 2 | 3 | 4 | 5 | 6 | 7 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 10747	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7578	MAFLD: How is it different from NAFLD?
Viewed By 5463	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4918	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4852	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

MOST CITED (2023-2025)

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: cmh_journal@ijpnc.com

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1473

TOTAL : 2708438